Clinical trials: Pharmacogenetic Testing
Chronic Kidney Disease, Hypertension
Genetic Testing to Understand and Address Renal Disease Disparities Across the United States Pharmacogenetic Substudy
This is a substudy of GUARDD-US (Genetic testing to Understand and Address Renal Disease Disparities across the United States, NCT04191824).
- Trial name
- GUARDD-US PGx (NCT06748040)
- Testing
- Timing of return of results
- Where
- 8 sites in United States
- Volunteers
- 1,874 people
- Sponsor
- Duke University
Adverse Drug Reaction (ADR)
Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System
This project addresses the problem of adverse drug reactions in the three most frequently prescribed therapeutic classes of drugs in children: antibiotics, analgesics, and mental health medications.
- Trial name
- NCT04249375
- Where
- 2 sites in Canada
- Volunteers
- 150 people
- Sponsor
- University of British Columbia
Cancer, Depression
Pharmacogenomic Testing to Personalize Supportive Oncology
The purpose of this study is to evaluate pharmacogenomics (PGx) guided drug prescribing for pain and depression in patients with cancer.
- Conditions
- Cancer, Depression, Pain
- Trial name
- NCT04500301
- Testing
- Preemptive Pharmacogenomic Testing
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Wake Forest University Health Sciences
Pharmacogenetics, Pharmacogenomic Drug Interaction
An Evaluation of the Impact of Pharmacist Personalized Medication Reviews With and Without a Discussion of Pharmacogenomic Results in an Employee Health Program.
The goal of this prospective randomized clinical trial is to learn if a pharmacist-provided personalized medication review (PMR) that discusses pharmacogenomic test results will improve medication outcomes.
- Trial name
- MyPGx (NCT06660264)
- Testing
- Pharmacist Personalized Medication Review (PMR), Discussion of Pharmacogenomic results during the PMR
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- University of Pittsburgh
Gastrointestinal Diseases
Utility of Pharmacogenomic Testing in Patients With Gastrointestinal Disorders
Researchers are trying to learn more about how individuals break down and process specific medications based on their genes. Pharmacogenomics (PGx) is a new, specialized field within individualized medicine.
- Trial name
- NCT05572593
- Testing
- Pharmacogenomics (PGx) genetic testing
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Mayo Clinic
Colorectal Cancer
Implementing Preemptive Pharmacogenomic Testing for Colorectal Cancer Patients in a Community Oncology Clinic
Pharmacogenomics (PGx) studies the interactions between an individuals genes and medications. PGx testing identifies genes within an individual that may affect treatment, efficacy, and toxicity of drugs.
- Trial name
- CRCPGx (NCT03187184)
- Testing
- OneOme RightMed®
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Essentia Health
Hypercholesterolemia, Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction
Genetically Guided Statin Therapy
The purpose of this study is to examine if using genetics can improve statin adherence in patients who should be taking statins but are not because of prior side effects.
- Trial name
- NCT01894230
- Testing
- SLCO1B1*5 allele testing, results reported at randomization, SLCO1B1*5 allele testing, results reported at end of study, Genetic testing for SLCO1B1*5 allele
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Duke University
Heart Failure With Reduced Ejection Fraction
Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score
The purpose of this trial is to better understand how the beta-blocker metoprolol works in people with Heart Failure with Reduced Ejection Fraction (HFrEF) according to participants genetics.
- Trial name
- NCT07490067
- Testing
- Metoprolol Succinate, Beta-Blocker Polygenic Score, Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Michigan
Anemia, Cardiovascular Disease
An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial
The purpose of Study 20060172 was to measure echocardiographic parameters and biomarkers in a subgroup of study subjects enrolled in Study 20050222 (the RED-HF Trial).
- Conditions
- Anemia, Cardiovascular Disease, Congestive Heart Failure, Heart Failure
- Trial name
- NCT00534456
- Testing
- Darbepoetin alfa
- Volunteers
- 12 people
- Sponsor
- Amgen
Depressive Disorder, Major, Depression
Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder
Evidence exists supporting the ability of genetic variations to influence patient drug response and side effects. Previous studies utilizing an open-label design have shown significant improvement in major depressive disorder…
- Conditions
- Depressive Disorder, Major, Depression, Depressive Disorder
- Trial name
- NCT02466477
- Testing
- GeneSight Psychotropic (GEN), Enhanced-GeneSight Psychotropic (E-GEN), Treatment as Usual (TAU)
- Where
- 14 sites in Canada
- Volunteers
- 542 people
- Sponsor
- Assurex Health Inc.
Mental Health, Depressive Disorder
Assessing the Impact of the Personalized Medicine Clinic on Mental Health Outcomes
The aim of this study is to investigate if personalized dosing of antidepressant medications using information gathered at the Personalized Medicine Clinic can improve patients' mental health.
- Conditions
- Mental Health, Depressive Disorder, Pharmacogenetic Testing, Antidepressant
- Trial name
- NCT07601477
- Testing
- Personalized Medicine Clinic
- Volunteers
- 200 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Gastroesophageal Reflux
Implementation of PPI Medication PGX Testing
Using genetic information about the individual to pick the right drug for the right disease at the right dose defines personalized medicine.
- Trial name
- PGX (NCT02794844)
- Testing
- Genotype Guided PPI Dosing
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Nemours Children's Clinic
Diabetes, Hypercholesterolaemia
The Effect of Providing Genetic Risk Information on Lifestyle Behaviors in African Americans
Cardiovascular disease (CVD) is a major and persistent health disparity for African Americans. Linking GAINS is a randomized pilot and feasibility study designed to evaluate whether receiving genetic risk information early in a…
- Conditions
- Diabetes, Hypercholesterolaemia, Hypertension, Obesity Type 2 Diabetes Mellitus
- Trial name
- LINKING GAINS (NCT07833384)
- Testing
- Color Genomics Genetic Testing Panels
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pennington Biomedical Research Center
Pharmacogenetic Testing to Determine Pharmacological Treatment in PTSD
Personalized Pharmacotherapy Using Pharmacogenetics in Veterans
This study is an observational clinical trial aimed at to evaluate the use of pharmacogenetic testing (PGx) for mental health treatment in members and Veterans of the CAF and RCMP patient population as well as the attitudes of…
- Trial name
- PGx (NCT06335043)
- Testing
- Pharmacogenetics Testing
- Where
- Canada
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Hypercholesterolemia, HMG COA Reductase Inhibitor Adverse Reaction
Statin Therapy to Improve Medication Adherence
The purpose of this pilot study is to examine if using genetics can improve statin adherence in patients who should be taking statins but are not because of prior side effects with statins.
- Trial name
- NCT01894217
- Testing
- Genetic testing and reporting for SLCO1B1*5 allele
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- Duke University
Tuberculosis Infection, Isoniazid Adverse Reaction
Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
This trial is designed to determine whether modifying the dose of isoniazid for individuals according to their n-acetyltransferase 2 (NAT2) genotype could increase the probability of achieving equivalence of area-under-the-curve.
- Trial name
- NCT05413551
- Testing
- Low-dose isoniazid, Standard dose of isoniazid, High-dose isoniazid
- Where
- Brazil
- Volunteers
- 78 people
- Sponsor
- Stanford University
Adverse Drug Reaction
PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions
PREPARE is an international, prospective, multi-center, open, randomized, cross-over implementation study assessing the impact of pre-emptive pharmacogenomic testing, of a panel of actionable pharmacogenomic variants, on adverse…
- Trial name
- PREPARE (NCT03093818)
- Testing
- Pharmacogenomic testing
- Where
- 7 sites in Austria, Greece and 5 more
- Volunteers
- 6,950 people
- Sponsor
- J.J.Swen
Pharmacogenomics, Polypharmacy
Pharmacogenomic Testing in a Program of All-inclusive Care for the Elderly (PACE) Setting
Tabula Rasa HealthCare (TRHC), doing business as CareKinesis, is the first national pharmacy that provides science-based medication risk identification and mitigation technologies and services.
- Trial name
- NCT05053815
- Testing
- Pharmacogenomic Testing
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Tabula Rasa HealthCare
Admitted Multimorbid Patients
Implementation of Pharmacogenetic Testing in Hospital Wards
The purpose of this study is to investigate whether it is feasible to implement pharmacogenetic testing as part of medication review while the patient is admitted to hospital.
- Trial name
- FAGLIS (NCT04573491)
- Testing
- Pharmacogenetic test, Medication review
- Where
- Norway
- Volunteers
- 46 people
- Sponsor
- Hospital Pharmacy Enterprise, South Eastern Norway
Gastrointestinal Cancer, Head and Neck Cancer
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
Doctors leading this study hope to find out if giving study participants' genetic information to cancer care providers will help personalize chemotherapy dosing decisions and decrease common chemotherapy side effects.
- Conditions
- Gastrointestinal Cancer, Head and Neck Cancer, Dihydropyrimidine Dehydrogenase Deficiency, UGT1A1 Gene Mutation
- Trial name
- NCT04541381
- Testing
- Availability of clinical decision support based on pharmacogenomic results.
- Where
- United States
- Volunteers
- 860 people
- Sponsor
- University of Chicago